Health-Related Quality of Life, Functional Decline, and Long-Term Mortality in Older Patients Following Hospitalisation Due to COVID-19

Marte Walle-Hansen (✉ marte@hansencorp.eu)
Bærum Sykehus

Anette Ranhoff
Diakonhjemmet Hospital

Marte Mellingsæter
Akershus University Hospital

Marte Wang-Hansen
Sykehuset i Vestfold

Marius Myrstad
Bærum Sykehus

Research Article

Keywords: COVID-19, Health-related quality of life, Geriatric Medicine, Pandemic

DOI: https://doi.org/10.21203/rs.3.rs-150067/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Older people are particularly vulnerable to severe COVID-19. Little is known about long-term consequences of COVID-19 on health-related quality of life and functional status in older people, and the impact of age in this context. We aimed to study age-related change in health-related quality of life (HR-QoL), functional decline and mortality among older patients six months following hospitalisation due to COVID-19.

Methods

This was a cohort study including patients aged 60 years and older admitted to four general hospitals in South-Eastern Norway due to COVID-19, from March 1 up until July 1, 2020. Patients who were still alive were invited to attend a six-month follow-up. Change in HR-QoL and functional status compared to before the COVID-19 hospitalisation were assessed using the EuroQol 5-dimensional-5 levels questionnaire (EQ 5D-5L). A change in visual analogue scale (VAS) score of 7 or more was considered clinically relevant.

Results

Out of 216 patients aged 60 years and older that were admitted to hospital due to COVID-19 during the study period, 171 were still alive 180 days after hospital admission, and 106 patients (62%) attended the six-month follow-up. Mean age was 74.3 years, 27 patients (26%) had experienced severe COVID-19. 57 participants (54%) reported a decrease in the EQ5D-5L VAS score after six months, with no significant difference between persons aged 75 years and older compared to younger. 70 participants (66%) reported a negative change in any of the dimensions of the EQ-5D-5L, with impaired ability to perform activities of daily life (35%), reduced mobility (33%) and having more pain or discomfort (33%) being the most commonly reported changes. 46 participants (43%) reported a negative change in cognitive function compared to before the COVID-19 hospitalisation. Six-month mortality was 21%, and increased with increasing age.

Conclusions

More than half of the patients reported a negative change in HR-QoL six months following hospitalisation due to COVID-19, and one out of three experienced a persistently impaired mobility and ability to carry out activities of daily living. The results suggest awareness of long-term functional decline in older COVID-19 patients.

Background
The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with over 83 million confirmed cases and over 1.8 million deaths globally by January 3, 2021 (1).

The number of deaths and confirmed cases of coronavirus disease (COVID-19) differ dramatically between countries. Norway, with its 5.5 million inhabitants has had a relatively low number of confirmed cases. By December 1, 2020 the cumulative number of people admitted to hospital with COVID-19 in Norway was 1728 (2). In concordance with international data, the majority of hospitalised patients have been aged 60 years and older (3).

Old age increases the risk of severe COVID-19 and constitutes the most prominent risk factor for in-hospital mortality due to COVID-19 (4).

COVID-19 primarily affects the lungs and the majority of hospital patients present with respiratory symptoms and fever (5). In older people, acute functional decline, confusion and asthenia are also commonly reported symptoms (6, 7). COVID-19 causes hypoxemia, and prolonged oxygen treatment requirement is associated with increased length of hospitalisation, with risk of immobilisation and acute sarcopenia (8). In general, immobilisation during acute illness can cause loss of physical functions with impact on activities of daily living (ADL) (9, 10). In some older people, hospitalisation causes persistent functional decline (11). So far, few studies have reported long-term consequences of COVID-19 (12). The role of age, for functional decline in older people who survive acute and severe disease is largely unknown. Increased knowledge about determinants of functional capacity following hospitalisation due to COVID-19, is imperative to develop preventive measures in patients at risk.

Cognitive and physical function are among the most important factors for quality of life and independent living in older people. Health-related quality of life (HR-QoL) is an important measure used to assess patients’ perception of the impact of disease and disability on different dimensions of health (13). A few studies suggest the pandemic might influence HR-QoL in general, and that older people might have higher risk of experiencing reduced HR-QoL during the pandemic than younger (14). To our best knowledge, only a few studies have reported post-discharge symptoms and HR-QoL in patients hospitalised due to COVID-19 (12, 15, 16). Long-term changes in HR-QoL, functional status and the ability to carry out ADL in older people following hospitalisation due to COVID-19, have been sparsely investigated until now.

In a six-month follow-up, we aimed to study age-related change in HR-QoL, functional status and mortality among patients aged 60 years and older after hospitalisation due to COVID-19.

**Methods**

**Study population**

This was a multi-centre cohort study including patients aged 60 years and older who were admitted to four general hospitals in South-Eastern Norway due to COVID-19 from March 1 up until July 1, 2020. The
patients were identified from administrative hospital data. All patients who were still alive 180 days after hospital admission were invited to participate in the study.

The participating centres were Akershus University Hospital, Bærum Hospital, Vestre Viken Hospital Trust, Diakonhjemmet Hospital and Vestfold Hospital Trust. Together, the four hospitals serve about 1 125 000 inhabitants in the Oslo Region, Norway. This comprises around 20% of the total Norwegian population.

COVID-19 was diagnosed by qualitative detection of nucleic acid from SARS-CoV-2 in throat or nasal secretions by use of real-time polymerase chain reaction. Patients with SARS-CoV-2 without symptoms of COVID-19 hospitalised for any other reasons, were not considered for inclusion. All eligible patients received an invitation letter to participate in the study and to attend a follow-up consultation at their respective hospital around six months after hospitalisation. For disabled patients, home visits or visits to nursing homes were arranged.

**Measurements**

Characteristics of the participants, including comorbidity and work status were obtained from hospital records. We registered whether the patient had experienced severe or critical acute COVID-19 illness, defined as admission to an intensive care or intermediary care unit (ICU), and the length of hospitalisation.

HR-QoL and functional status six months after hospitalisation were assessed using the EuroQol 5-dimensional-5 levels (EQ 5D-5L) questionnaire (17). The EQ 5D-5L includes a vertical visual analogue scale (VAS) from 0-100 rating overall HR-QoL. Furthermore, the tool assesses functional status with five dimensions (mobility, self-care, usual activities, pain/discomfort and depression/anxiety), each with five levels of function (no problems, slight problems, moderate problems, severe problems and unable to/extreme problems).

Premorbid HR-QoL and functional status (defined as two weeks prior to COVID-19 symptom onset) were reported retrospectively at six months after hospital admission. The majority of patients replied to the premorbid HR-QoL at home before attending the follow-up consultation, while status after six months was filled out as a part of the study visit. For disabled and cognitively impaired patients, the HR-QoL questionnaires were answered with the help of a next-of-kin.

Patient-reported outcome measure on change in cognitive function compared to two weeks before the onset of COVID-19 symptoms, was assessed with the following questions: *Has your cognitive function changed?* (appendix p 3).

We used the Montreal Cognitive Assessment (MoCA) to evaluate cognitive capacity, and the Short Physical Performance Battery (SPPB) to assess functional capacity (18, 19). Height and weight were measured as a part of the study visit.
In-hospital mortality was defined as death during the index hospital stay, related or unrelated to COVID-19, and was obtained from hospital records. Six-month mortality was defined as death related or unrelated to COVID-19 within 180 days after the index hospital admission date. Mortality status 180 days after hospital admission was based on reports from hospital electronic patient record systems, which update weekly from the Norwegian National Death Register.

**Statistical methods**

We used the registry tool EpiData entry client version 4.4.3.1 (The EpiData Association, Odense, Denmark). Continuous variables are presented as mean ± standard deviation and categorical variables as number (%). We used Student’s t test for means of continuous variables and Pearson's Chi-square test of independence for categorical variables to compare characteristics of study participants aged under 75 years with participants aged 75 years and older. P-values < 0.05 were considered statistically significant.

We present change in HR-QoL as the mean change in EQ 5D-5L VAS (0-100) by age group and disease severity, as well as the percentage of survivors reporting a minimally clinically important difference in scores before compared to after hospitalisation due to COVID-19. We defined a clinically important difference as a change in the VAS of 7 or more (20). We present change in functional status as the mean change in each of the five EQ 5D-5L dimensions (mobility, self-care, usual activities, pain and anxiety) by age group, as well as the percentage of survivors reporting worsened function for each of the dimensions.

In-hospital mortality and six-month mortality was calculated with the total number of patients over 60 years of age who were hospitalised due to COVID-19 during the study period as denominator, and is reported as % by age group. We present six-month mortality by age group as Kaplan-Meier plots.

All statistical analyses were conducted using SPSS version 26.0 (IBM, Armonk, NY, USA).

**Ethical considerations**

Patients who were alive at six months after hospitalisation, and able to receive and understand information about the study, signed a written informed consent to participate. If the patient was not able to consent, a passive consent to participate was assumed. The patient’s proxy was then informed about the study and could withdraw participation on behalf of the patient. The need for written informed consent from the proxy of patients who were unable to consent was waived by the Norwegian Regional Committees for Medical and Health Research Ethics (REC Central, reference number 155425), due to the retrospective nature of the study, and that participation would imply minimal risk or disadvantage for the participants. Patients who died were included with patient administrative data only, and the need for informed consent was waived by the REC Central (reference number 155425) due to the retrospective nature of the study. Participants or next-of-kin were at any time able to withdraw from the study.

The study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics (REC Central, reference number 155425) and the officers of data protection at all the participating centres, and complies with the Declaration of Helsinki.
Results

In total, 216 patients aged 60 years and older were hospitalised due to COVID-19 during the study period. Out of 171 persons who were still alive six months after hospital admission and eligible for the study, 106 (62%) attended the six-month follow-up (median 186 days after discharge). Figure 1 shows the inclusion of participants to the study.

Study population

Table 1 shows characteristics of the study population by age group. Mean age was 74.3 (range 60–96) years and 60 patients (57%) were men. 27 patients (26%) had experienced severe or critical acute COVID-19, defined as ICU or intermediary unit care during hospitalisation. The mean length of hospitalisation was 11.6 (range 1–67) days. The proportion with severe COVID-19 was higher in the youngest age group. Comorbid conditions were more prevalent in the oldest age group. The mean sum scores of both MoCA and SPPB were lower in the oldest age group, indicating lower cognitive and physical function in older compared to younger participants.
Table 1
Study population characteristics at six-month follow-up by age group

|                                 | < 75 years old | ≥ 75 years old | p-value |
|---------------------------------|----------------|---------------|---------|
|                                 | n = 61         | n = 45        |         |
| Age (mean, SD)                  | 68.4 (4.6)     | 82.4 (5.3)    | < 0.05  |
| Male gender                     | n (%)          | n (%)         |         |
| Current or previous smoking1    | 30 (50)        | 26 (59)       | 0.36    |
| Severe acute disease2           | 22 (36)        | 5 (11)        | < 0.05  |
| Length of hospital stay (mean, SD) | 12.5 (12.5)   | 10.3 (12.1)   | 0.37    |
| **Work status3**                |                |               | < 0.05  |
| Full time or part time employed | 18 (30)        | 0 (0)         |         |
| Sick leave, retirement or disability advantages | 42 (69) | 45 (100) |         |
| **Comorbidities**               |                |               |         |
| Hypertension                    | 22 (36)        | 19 (42)       | 0.52    |
| Cardiac conditions              | 12 (20)        | 22 (49)       | < 0.05  |
| COPD4 or asthma                 | 18 (30)        | 11 (24)       | 0.56    |
| Diabetes mellitus               | 10 (16)        | 6 (13)        | 0.66    |
| Dementia                        | 0 (0)          | 5 (11)        | < 0.05  |
| Overweight (BMI >30)5           | 16 (28)        | 6 (16)        | 0.20    |
| Other6                          | 9 (15)         | 14 (31)       | < 0.05  |
| **Cognitive capacity**          |                |               |         |
| MoCA score Total (0–30)7        | 25.3 (3.8)     | 21.7 (5.8)    | < 0.05  |
| **Functional capacity**         |                |               |         |
| SPPB total score (0–12)8        | 10.6 (2.3)     | 7.8 (3.1)     | < 0.05  |

Patients aged 60 years and older admitted to four Norwegian hospitals from March 1 to July 1, 2020 due to COVID-19, and still alive after six months, n = 106.  
1 Missing data for 2 patients.  
2 Admission to intensive care unit or intermediary ward during hospitalisation.  
3 Missing data for 1 patient.  
4 Chronic obstructive pulmonary disease.  
5 Missing data for 11 patients.  
6 Including active cancer, previous
depression, chronic kidney disease or previous brain stroke). incomplete or missing data for 14 participants. 6 patients did not perform the SPPB.

HR-QoL, functional decline and patients-reported outcome measures

Out of 106 participants, 57 (54%) reported a decrease of more than 7 points in the EQ5D-5L VAS score, compared to before the hospital admission. Mean VAS score was 77.0 (SD 16.7) before admission and 65.8 (SD 19.1) after six months (mean change −11.5 (SD 14.2)). Figure 2 shows mean changes in the EQ5D-5L VAS by age group. Older people had lower scores both before and after COVID-19, but the magnitude of change did not differ between persons aged 75 years and older and younger people (mean change −10.3 (SD 12.8) vs. -12.3 (SD 15.1), p = 0.51). The share of patients who experienced a minimally clinically important change in VAS score did not differ between patients with severe or critical acute COVID-19 and less severe COVID-19 (68 vs. 53%, p = 0.20), but the magnitude of change was significantly larger among patients with severe or critical disease (mean change −17.6 (SD 16.2) vs. -9.5 (SD 13.0), p < 0.05).

Patients aged 60 years and older admitted to four Norwegian hospitals from March 1 to July 1 2020 due to COVID-19, and still alive after six months, n = 106. For 6 participants, information on EQ 5D VAS scale was incomplete: 4 participants missed both status before and six months after COVID-19, and 2 participants missed status after 6 months.

While 35 (33%) and 37 patients (35%), respectively, reported a decline in mobility and the ability to perform activities of daily living compared to before COVID-19, 35 patients (33%) reported having more pain or discomfort, 28 patients (26%) increased anxiety and 18 patients (17%) a decline in the ability in self-care. 11 patients (10%) reported a major change (a decrease of two or more functional levels) in mobility and 12 patients (11 %) in usual activities. Table 2 demonstrates mean change in EQ5D-5L dimensions by age group.
Table 2
Mean change in EQ5D-5L dimensions by age group

| Dimensions¹ | < 75 years old | ≥ 75 years old | p-value |
|-------------|----------------|----------------|---------|
|             | n = 61         | n = 45         |         |
| Mobility    |                |                |         |
| Mean score before COVID-19 | 1.3 (0.7) | 1.6 (0.9) | 0.15   |
| Mean score after 6 months    | 1.8 (1.0) | 2.0 (1.0) | 0.32   |
| Mean change                   | -0.4 (0.8) | -0.4 (0.8) | 0.87   |
| Self-care                    |                |                |         |
| Mean score before COVID-19 | 1.1 (0.4) | 1.4 (0.8) | < 0.05 |
| Mean score after 6 months    | 1.3 (0.7) | 1.6 (1.0) | 0.06   |
| Mean change                   | -0.2 (0.6) | -0.3 (0.7) | 0.68   |
| Usual activities             |                |                |         |
| Mean score before COVID-19 | 1.3 (0.6) | 1.7 (1.1) | < 0.05 |
| Mean score after 6 months    | 1.7 (1.1) | 2.2 (1.2) | < 0.05 |
| Mean change                   | -0.5 (0.9) | -0.5 (0.9) | 0.68   |
| Pain                        |                |                |         |
| Mean score before COVID-19 | 1.7 (0.8) | 1.8 (0.9) | 0.36   |
| Mean score after 6 months    | 2.0 (0.9) | 2.1 (0.9) | 0.40   |
| Mean change                   | -0.3 (0.6) | -0.3 (0.6) | 0.96   |
| Anxiety                      |                |                |         |
| Mean score before COVID-19 | 1.2 (0.5) | 1.4 (0.8) | 0.06   |
| Mean score after 6 months    | 1.5 (0.8) | 1.8 (1.1) | 0.16   |
| Mean change                   | -0.4 (0.6) | -0.3 (0.8) | 0.70   |

Patients aged 60 years and older admitted to four Norwegian hospitals from March 1 to July 1, 2020 due to COVID-19, and still alive after six months, n = 106.¹ Incomplete data for 3 participants: 1 participant missing premorbid level of self-care, 1 participant missing premorbid and six months status for pain, as well as premorbid score for anxiety, and finally 1 participant missing premorbid and six month status for anxiety.
Figures 3a-3e demonstrate changes in dimension-specific EQ 5D-5L scores by age group. Older people had lower functional status, but the change in functional status did not differ between the age groups in any of the dimensions.

Patients aged 60 years and older admitted to four Norwegian hospitals from March 1 to July 1 2020 due to COVID-19, and still alive after six months, n = 106.

46 of the participants (43%) experienced a negative change in cognitive function six months after the COVID-19 hospitalisation, with a a higher proportion reporting cognitive decline among persons 75 years and older, compared to younger persons (59% vs. 37%, p < 0.05).

**Mortality**

In-hospital mortality was 16% (34 out of 216 patients). Six-month mortality was 21% (45 out of 216) patients, 36% in patients aged 75 years and older (35 out of 98 patients) and 8% in patients aged 60 to 74 years (10 out of 118 patients) (p < 0.05). 11 patients (5%) died out of hospital. Figure 4 shows Kaplan-Meier survival plots by age group.

Patients aged 60 years and older admitted to four Norwegian hospitals from March 1 to July 1, 2020, due to COVID-19, n = 216.

**Discussion**

To our knowledge, this is the first study to report long-term impact of COVID-19 on HR-QoL and functional status in older people.

More than half of the study participants reported a clinically relevant decline in HR-QoL six months after hospitalisation due to COVID-19, compared to before hospital admission. One out of three patients reported decline in mobility and the ability to carry out activities of daily living. We found no difference in functional decline six months after hospitalisation due to COVID-19 when comparing patients aged 75 years or older with patients aged under 75 years. Still, the oldest patients reported lower functional status, possibly increasing their risk of permanent care needs and loss of independence following hospitalisation due to COVID-19. The results of our study suggest awareness of long-term functional decline in older COVID-19 patients, and sends the message to prevent both the disease and its complications in this vulnerable group of patients.

Reports about persistent symptoms among patients who have suffered from COVID-19 are emerging, and studies of long-term consequences of the disease are highly warranted (21). So far, knowledge on HR-QoL in survivors is very sparse (16), and we are not aware of any studies that have studied older patients with this regard.

In a recently published paper, Huang, et al, reported persistent symptoms among patients with a median age of 57 years, after hospitalisation due to COVID-19 in China (12). Interestingly, the mean EQ 5D-5L VAS...
at six months was much lower in our study compared to in the patients in China (65.8 vs. 80.9), and very few patients in the Chinese study had problems with mobility or ADL. The most likely explanations for these differences are the much higher mean age, more comorbidity, and a higher proportion of patients with severe disease and ICU treatment, in our study. Patients who had experienced severe COVID-19 had the largest decline in HR-QoL in our study. The results suggest that special attention regarding long-term reduction of HR-QoL and functional decline should be drawn to the oldest patients and patients with severe COVID-19.

Functional loss during hospitalisation due to acute illness is common in older people. It reduces their ability to live independently, and increases the risk of nursing home admission and needs of community care (22–24). In a recently published study that included 346 patients aged 65 years and older with confirmed seasonal influenza and other acute respiratory illness, 18% experienced persistent functional decline 30 days after discharge from hospital (11). The functional losses were equivalent between patients with influenza and other acute respiratory illnesses. Whether COVID-19 might cause more severe long-term reduction in HR-QoL and functional capacity compared to other acute conditions, remains an unanswered question that should be addressed in further studies.

Many patients with COVID-19 require long-term oxygen treatment, and both persistent hypoxemia and isolation measures might promote immobilisation and delirium. Immobilisation due to acute illness increases the risk of acute sarcopenia and loss of physical function (8). Sarcopenia is furthermore associated with negative impact on HR-QoL (25). Emerging evidence suggest that older patients with COVID-19 are at high risk of developing delirium, a condition associated with both increased mortality and long-term cognitive impairment and dementia (26, 27).

Prevention of hospital admission due to COVID-19 with vaccination of older people might be an effective measure to prevent long-term functional decline. Furthermore, management of complications such as immobilisation and delirium, might prevent long-term functional loss, and should be implemented subsequently in older patients hospitalised with COVID-19.

**Strengths and limitations**

The main strengths of this study is the long follow-up generating new knowledge about the persisting impact of the lives of older people who have survived severe COVID-19. Furthermore, the study population represents a high proportion of older survivors after hospitalisation due to COVID-19 in Norway. Also, the multicentre design supports the generalisability of our result.

This study has some limitations. We made use of the EQ 5D-5L response form, which was scored retrospectively for the premorbid status at six months. The response in premorbid status might be influenced by experiences during hospitalisation, the patient’s current health status or the psychosocial effect of the pandemic situation in itself, leading to under- or over reporting of symptoms. To prevent potential bias from patients reporting only small changes in the EQ 5D VAS scale, we chose a cut-off
value of 7 points as the minimally clinically important difference when comparing scores before and after discharge from hospital (20).

Patients were evaluated at a single point follow-up at six months. We experienced that some patients with a high degree of comorbidity or anamnestic great loss of function after COVID-19 were unwilling to participate in the study because of the resources demanded in meeting at the hospital. Home visits or institutional consultations were arranged to include as many of these patients as possible, but we still suspect that the frailest group is underrepresented in our study, potentially leading to underestimation of both symptoms and the magnitude of functional decline at 6 months.

**Conclusions**

This study is among the first to address long-term change in HR-QoL and functional decline among older people hospitalised due to COVID-19. More than half of patients aged 60 years and older reported a negative change in HR-QoL six months after hospitalisation due to COVID-19. One out of three experienced a persistent loss of physical function and ability to carry out ADL, with no difference between the age groups studied. Six-month mortality increased with increasing age, and was very high among patients 75 years or older. These results highlight the importance of preventing COVID-19 in older people, and to prevent functional decline in older patients hospitalised due to COVID-19.

**List Of Abbreviations**

**ADL**
Activities of daily living

**COVID-19**
Coronavirus disease

**EQ 5D-5L**
EuroQol 5-dimensional-5 levels questionnaire

**HR-QoL**
Health-related quality of life

**ICU**
Intensive Care Unit

**MoCA**
Montreal Cognitive Assessment

**SARS-CoV-2**
Acute respiratory syndrome coronavirus 2

**SPPB**
Short Physical Performance Battery

**VAS**
Visual Analogue Scale
Declarations

Ethics approval and consent to participate

Patients who were alive at six months after hospitalisation, and able to receive and understand information about the study, signed a written informed consent to participate. If the patient was not able to consent, a passive consent to participate was assumed. The patient’s proxy was then informed about the study and could withdraw participation on behalf of the patient. The need for written informed consent from the proxy of patients who were unable to consent was waived by the Norwegian Regional Committees for Medical and Health Research Ethics (REC Central, reference number 155425), due to the retrospective nature of the study, and that participation would imply minimal risk or disadvantage for the participants. Patients who died were included with patient administrative data only, and the need for informed consent was waived by the REC Central (reference number 155425) due to the retrospective nature of the study. Participants or next-of-kin were at any time able to withdraw from the study.

The study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics (REC Central, reference number 155425) and the officers of data protection at all the participating centres, and complies with the Declaration of Helsinki.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The study was funded by an internal research grant from Bærum Hospital, Vestre Viken Hospital Trust, and by The Norwegian Society of Geriatric Medicine and The Kavli Research Centre for Aging and Dementia.

Authors’ contributions

AHR and MMy were involved in the conception and design of the study. MMWH coordinated the study. MMWH, AHR, MWH and MMe were responsible for data collection. MMWH and MMy wrote the first draft. MMy was in charge of data analysis. All authors read and approved the final manuscript.

Acknowledgements
We thank all doctors and physiotherapists who have contributed to data collection, as well as all patients who have participated in this study. A special thanks to Anne Kristine Gulsvik, who has also contributed to the protocol.

References

1. Weekly epidemiological update – 3 January 2021: World Health Organization; 2021 [Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update—5-january-2021. Accessed 9 January 2021.

2. Daily report and statistics about coronavirus and COVID-19: Norwegian Institute of Public Health; 2020 [Available from: https://www.fhi.no/en/id/infectious-diseases/coronavirus/daily-reports/daily-reports-COVID19/. Accessed 9 December 2020.

3. COVID-19 Ukerapport – uke 48: The Norwegian Institute of Public Health; 2020 [Available from: https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdf381ab52e6157/vedlegg/andre-halvar-2020/2020.12.02-ukerapport-uke-48-covid-19.pdf. Accessed December 7 2020.

4. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. Bmj. 2020;369:m1985.

5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama. 2020;323(20):2052–9.

6. Zerah L, Baudouin É, Pépin M, Mary M, Krypciak S, Bianco C, et al. Clinical Characteristics and Outcomes of 821 Older Patients with SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards. J Gerontol A Biol Sci Med Sci. 2020.

7. Poco PCE, Aliberti MJR, Dias MB, Takahashi SF, Leonel FC, Altona M, et al. Divergent: age, frailty, and atypical presentations of COVID-19 in hospitalized patients. J Gerontol A Biol Sci Med Sci. 2020.

8. Welch C, Greig C, Masud T, Wilson D, Jackson TA. COVID-19 and Acute Sarcopenia. Aging Dis. 2020;11(6):1345–51.

9. Aarden JJ, van der Schaaf M, van der Esch M, Reichardt LA, van Seben R, Bosch JA, et al. Muscle strength is longitudinally associated with mobility among older adults after acute hospitalization: The Hospital-ADL study. PLoS One. 2019;14(7):e0219041.

10. Liu JYJ, Reijnierse EM, van Ancum JM, Verlaan S, Meskers CGM, Maier AB. Acute inflammation is associated with lower muscle strength, muscle mass and functional dependency in male hospitalised older patients. PLoS One. 2019;14(4):e0215097.

11. Andrew MK, MacDonald S, Godin J, McElhaney JE, LeBlanc J, Hatchette TF, et al. Persistent Functional Decline Following Hospitalization with Influenza or Acute Respiratory Illness. Journal of the American Geriatrics Society.n/a(n/a).
12. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220–32.
13. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(2 Suppl 3):73–81.
14. Ping W, Zheng J, Niu X, Guo C, Zhang J, Yang H, et al. Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic. PLoS One. 2020;15(6):e0234850.
15. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020.
16. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2020.
17. Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, et al. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Qual Life Res. 2019;28(1):141–52.
18. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94.
19. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.
20. Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SSC, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493–500.
21. Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. Long-term consequences of COVID-19: research needs. The Lancet Infectious Diseases. 2020;20(10):1115–7.
22. Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003;51(4):451–8.
23. Sager MA, Franke T, Inouye SK, Landefeld CS, Morgan TM, Rudberg MA, et al. Functional outcomes of acute medical illness and hospitalization in older persons. Arch Intern Med. 1996;156(6):645–52.
24. Fortinsky RH, Covinsky KE, Palmer RM, Landefeld CS. Effects of functional status changes before and during hospitalization on nursing home admission of older adults. J Gerontol A Biol Sci Med Sci. 1999;54(10):M521-6.
25. Beaudart C, Reginster JY, Petermans J, Gillain S, Quabron A, Locquet M, et al. Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Exp Gerontol. 2015;69:103–10.
26. Pendlebury ST, Lovett NG, Smith SC, Dutta N, Bendon C, Lloyd-Lavery A, et al. Observational, longitudinal study of delirium in consecutive unselected acute medical admissions: age-specific rates and associated factors, mortality and re-admission. BMJ Open. 2015;5(11):e007808.
27. Davis DH, Muniz-Terrera G, Keage HA, Stephan BC, Fleming J, Ince PG, et al. Association of Delirium With Cognitive Decline in Late Life: A Neuropathologic Study of 3 Population-Based Cohort Studies. JAMA Psychiatry. 2017;74(3):244–51.